Press Releases

Print Page Print Page        E-mail Page Email Page        RSS Feeds RSS        E-mail Alerts Email Alerts        Financial Tear Sheet Tear Sheet
Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010 | 2009
DateTitle 
12/09/13Alkermes Presents Data on Two Late-Stage Clinical Candidates, Aripiprazole Lauroxil and ALKS 5461, at 52nd Annual ACNP MeetingPrinter Friendly Version
11/05/13Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 2013 Healthcare ConferencePrinter Friendly Version
10/31/13Alkermes plc Reports Financial Results for Quarter Ended Sept. 30, 2013Printer Friendly Version
10/24/13Alkermes to Host Conference Call to Discuss Financial Results for Quarter Ended Sept. 30, 2013Printer Friendly Version
10/10/13Alkermes Receives Fast Track Designation for ALKS 5461 for Major Depressive DisorderPrinter Friendly Version
10/09/13Alkermes Announces Alignment with FDA on Plans for Pivotal Program for ALKS 5461 for Major Depressive DisorderPrinter Friendly Version
10/08/13Alkermes Announces Completion of Patient Enrollment in Pivotal Phase 3 Study of Aripiprazole LauroxilPrinter Friendly Version
09/30/13Alkermes Expands Senior Management TeamPrinter Friendly Version
09/03/13Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare ConferencePrinter Friendly Version
07/25/13Alkermes plc Reports Financial Results for Quarter Ended June 30, 2013Printer Friendly Version
07/18/13Alkermes to Host Conference Call to Discuss Financial Results for Quarter Ended June 30, 2013Printer Friendly Version
07/17/13Alkermes Announces Initiation of Phase 2 Clinical Study of ALKS 3831, Designed to Be a Broad Spectrum Oral Antipsychotic for the Treatment of SchizophreniaPrinter Friendly Version
07/17/13Alkermes Unveils Three New Drug Candidates Demonstrating Productivity of Its R&D CapabilitiesPrinter Friendly Version
07/10/13Alkermes Announces Webcast of R&D Day on July 17, 2013Printer Friendly Version
05/31/13Alkermes Presents Positive Results from Phase 2 Clinical Study of ALKS 5461 in Major Depressive Disorder at 53rd Annual NCDEU MeetingPrinter Friendly Version
05/29/13Alkermes’ Corporate Presentation to be Webcast at Two Upcoming ConferencesPrinter Friendly Version
05/28/13Alkermes Presents Positive Results from Phase 1 Study of ALKS 3831 as a Broad Spectrum Treatment for SchizophreniaPrinter Friendly Version
05/23/13Alkermes’ Corporate Presentation to be Webcast at the Deutsche Bank 38th Annual dbAccess Health Care ConferencePrinter Friendly Version
05/23/13Alkermes plc Reports Financial Results for Fiscal Year 2013 and Provides Financial ExpectationsPrinter Friendly Version
05/22/13Alkermes Announces Data on ALKS 5461 and ALKS 3831 to Be Presented at 53rd Annual NCDEU MeetingPrinter Friendly Version
05/16/13Alkermes to Host Conference Call to Discuss Financial Results for Fiscal Year 2013Printer Friendly Version
05/16/13Alkermes Elects Nancy Wysenski to Board of DirectorsPrinter Friendly Version
05/01/13Alkermes’ Corporate Presentation to be Webcast at the Bank of America Merrill Lynch 2013 Smid Cap ConferencePrinter Friendly Version
04/17/13Alkermes Announces Positive Results from Phase 2 Clinical Study of ALKS 5461 for Major Depressive DisorderPrinter Friendly Version
02/19/13Alkermes’ Corporate Presentation to be Webcast at Three Upcoming ConferencesPrinter Friendly Version
02/05/13Alkermes’ Corporate Presentation to be Webcast at Two Upcoming ConferencesPrinter Friendly Version
01/31/13Alkermes plc Reports Third Quarter Fiscal 2013 Financial ResultsPrinter Friendly Version
01/24/13Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2013Printer Friendly Version
01/03/13Alkermes Announces Notice of Allowance of Key U.S. Patent for Aripiprazole Lauroxil, a New Schizophrenia Drug CandidatePrinter Friendly Version
01/03/13Alkermes Expands CNS Pipeline and Announces Positive Results from Phase 1 Study of ALKS 3831, a Novel Antipsychotic Therapy for the Treatment of SchizophreniaPrinter Friendly Version
01/02/13Alkermes’ Corporate Presentation to be Webcast at the 31st Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version